21.11.2017 • NewsElaine BurridgeMomentiveIPO

Momentive Postpones IPO

(c) Corbis. All Rights Reserved.
(c) Corbis. All Rights Reserved.

MPM Holdings, also known as Momentive, has decided to postpone its proposed initial public offering (IPO), citing poor market conditions. The silicone and quartz producer filed in September with the US Securities and Exchange Commission to make an initial ipo with the aim of raising up to $100 million.

Commenting on the decision, President and CEO Jack Boss said: “While it is disappointing to have to postpone our initial public offering due to adverse market conditions, we had meaningful interest from the investment community in our company and have a strong financial position that will allow us to continue to execute against our multi-dimensional growth strategy.”

Boss noted that Momentive is focused on growing its specialty product portfolio as well as enhancing its global operations. “Our successes to date have been clearly demonstrated in our financial results and we are very excited about Momentive’s future growth prospects and outlook,” he said.

Momentive emerged from Chapter 11 bankruptcy protection in October 2014, having completed a restructuring plan that wiped out debts of around $3 billion. The company belongs to private equity group Apollo Global Management.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
21.03.2025 • News

What’s Next for Pharma Supply Chains?

Sudden shifts in demand, supply shortages and global collapse have put immense pressure on pharmaceutical logistics. To address these challenges, PHARMAP 2025 brings together industry experts to discover AI-driven supply chain optimisation, strategic logistics partnerships and digital solutions that enhance efficiency and resilience in the pharmaceutical supply chain.